Newly emerging evidence is informing best care for patients with polycythemia vera (PV). Not only are recently updated diagnostic criteria available for PV, but better ways to assess risk of thrombosis and disease progression are being discovered. Additionally, best practices for use of therapy is evolving. These and other aspects of care were discussed at a symposium on PV held during the US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes held August 4, 2017 in Philadelphia. This activity features the clinically-relevant content from that symposium.